WHO ICTRP trial
Phase Ib/II study of Linperlisib combination with Adebrelimab as second-line…
ChiCTR2400085148 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400085148 |
|---|---|
| Public title | Phase Ib/II study of Linperlisib combination with Adebrelimab as second-line treatment for advanced biliary tract cancer: a single-arm, open-label study |
| Scientific title | Phase Ib/II study of Linperlisib combination with Adebrelimab as second-line treatment for advanced biliary tract cancer: a single-arm, open-label study |
| Primary sponsor | The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Advanced biliary tract cancer |
| Interventions | Experimental group:Phase Ib(Safety run-in,N=6):Linperlisib:80mg QD oral in a 21-day cycle. Adebrelimab: 1200mg q3w intravenous drip in a 21-day cycle. Phase II(Expansion phase, N=28): Linperlisib: RP2D(recommended phaseII dose)QD… |
| Registration date | May 31, 2024 |
| Target size | Experimental group:34 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: